Similarly, anisonamide suppresses the growth of HCC and induces apoptosis by inhibiting NLRP3 expression and further inhibiting the activation of the NLRP3 inflammasome, thus reducing the production of IL-1β [124]. The gene discussed is NLRP3; the disease is hepatocellular carcinoma.